| Unanswered questions emerging from INDIGO data . |
|---|
| Optimal patient population and long-term benefits |
| What are the patients most likely to benefit from vorasidenib in the upfront setting? |
| Does the use of vorasidenib impact OS in the INDIGO population? |
| What is the optimal treatment sequence and duration of treatment with IDH inhibitors? |
| Will treatment with vorasidenib affect response to subsequent treatment with radiation therapy and chemotherapy? |
| What is the magnitude of benefit of vorasidenib in patients with gross total resection or minimal residual disease after surgery? |
| Are there cumulative long-term adverse events associated with the use vorasidenib? |
| Does vorasidenib affect fertility? Is it associated with teratogenic risk? |
| Use in other setting and trial design |
| What is the additive value of vorasidenib over standard of care therapy alone? |
| What is the role of vorasidenib in combination with SOC treatment in the up-front and recurrent settings? |
| Is there a benefit of starting vorasidenib after radiation and chemotherapy as maintenance treatment? |
| Is there a role for vorasidenib in patients with grade 3 or enhancing tumors? |
| Should patients who are receiving ivosidenib or olutasidenib off-label be switched to vorasidenib? |
| Biomarkers |
| What imaging methods and biomarkers can be used to improve response assessment? |
| What mechanisms mediate resistance to IDH inhibitors in glioma? How does this affect the treatment sequence? |
| What is the role of DNA methylation analysis in identifying potential responders versus non-responders to vorasidenib? Are there other potential predictive biomarkers? |
| Social burden |
| What is the patients’ burden (financial, family planning, etc) of long-term treatment with IDH inhibitors? |
| What is the cost-effectiveness associated with vorasidenib? |
| How to improve access to treatment in developing countries? |
| Unanswered questions emerging from INDIGO data . |
|---|
| Optimal patient population and long-term benefits |
| What are the patients most likely to benefit from vorasidenib in the upfront setting? |
| Does the use of vorasidenib impact OS in the INDIGO population? |
| What is the optimal treatment sequence and duration of treatment with IDH inhibitors? |
| Will treatment with vorasidenib affect response to subsequent treatment with radiation therapy and chemotherapy? |
| What is the magnitude of benefit of vorasidenib in patients with gross total resection or minimal residual disease after surgery? |
| Are there cumulative long-term adverse events associated with the use vorasidenib? |
| Does vorasidenib affect fertility? Is it associated with teratogenic risk? |
| Use in other setting and trial design |
| What is the additive value of vorasidenib over standard of care therapy alone? |
| What is the role of vorasidenib in combination with SOC treatment in the up-front and recurrent settings? |
| Is there a benefit of starting vorasidenib after radiation and chemotherapy as maintenance treatment? |
| Is there a role for vorasidenib in patients with grade 3 or enhancing tumors? |
| Should patients who are receiving ivosidenib or olutasidenib off-label be switched to vorasidenib? |
| Biomarkers |
| What imaging methods and biomarkers can be used to improve response assessment? |
| What mechanisms mediate resistance to IDH inhibitors in glioma? How does this affect the treatment sequence? |
| What is the role of DNA methylation analysis in identifying potential responders versus non-responders to vorasidenib? Are there other potential predictive biomarkers? |
| Social burden |
| What is the patients’ burden (financial, family planning, etc) of long-term treatment with IDH inhibitors? |
| What is the cost-effectiveness associated with vorasidenib? |
| How to improve access to treatment in developing countries? |
| Unanswered questions emerging from INDIGO data . |
|---|
| Optimal patient population and long-term benefits |
| What are the patients most likely to benefit from vorasidenib in the upfront setting? |
| Does the use of vorasidenib impact OS in the INDIGO population? |
| What is the optimal treatment sequence and duration of treatment with IDH inhibitors? |
| Will treatment with vorasidenib affect response to subsequent treatment with radiation therapy and chemotherapy? |
| What is the magnitude of benefit of vorasidenib in patients with gross total resection or minimal residual disease after surgery? |
| Are there cumulative long-term adverse events associated with the use vorasidenib? |
| Does vorasidenib affect fertility? Is it associated with teratogenic risk? |
| Use in other setting and trial design |
| What is the additive value of vorasidenib over standard of care therapy alone? |
| What is the role of vorasidenib in combination with SOC treatment in the up-front and recurrent settings? |
| Is there a benefit of starting vorasidenib after radiation and chemotherapy as maintenance treatment? |
| Is there a role for vorasidenib in patients with grade 3 or enhancing tumors? |
| Should patients who are receiving ivosidenib or olutasidenib off-label be switched to vorasidenib? |
| Biomarkers |
| What imaging methods and biomarkers can be used to improve response assessment? |
| What mechanisms mediate resistance to IDH inhibitors in glioma? How does this affect the treatment sequence? |
| What is the role of DNA methylation analysis in identifying potential responders versus non-responders to vorasidenib? Are there other potential predictive biomarkers? |
| Social burden |
| What is the patients’ burden (financial, family planning, etc) of long-term treatment with IDH inhibitors? |
| What is the cost-effectiveness associated with vorasidenib? |
| How to improve access to treatment in developing countries? |
| Unanswered questions emerging from INDIGO data . |
|---|
| Optimal patient population and long-term benefits |
| What are the patients most likely to benefit from vorasidenib in the upfront setting? |
| Does the use of vorasidenib impact OS in the INDIGO population? |
| What is the optimal treatment sequence and duration of treatment with IDH inhibitors? |
| Will treatment with vorasidenib affect response to subsequent treatment with radiation therapy and chemotherapy? |
| What is the magnitude of benefit of vorasidenib in patients with gross total resection or minimal residual disease after surgery? |
| Are there cumulative long-term adverse events associated with the use vorasidenib? |
| Does vorasidenib affect fertility? Is it associated with teratogenic risk? |
| Use in other setting and trial design |
| What is the additive value of vorasidenib over standard of care therapy alone? |
| What is the role of vorasidenib in combination with SOC treatment in the up-front and recurrent settings? |
| Is there a benefit of starting vorasidenib after radiation and chemotherapy as maintenance treatment? |
| Is there a role for vorasidenib in patients with grade 3 or enhancing tumors? |
| Should patients who are receiving ivosidenib or olutasidenib off-label be switched to vorasidenib? |
| Biomarkers |
| What imaging methods and biomarkers can be used to improve response assessment? |
| What mechanisms mediate resistance to IDH inhibitors in glioma? How does this affect the treatment sequence? |
| What is the role of DNA methylation analysis in identifying potential responders versus non-responders to vorasidenib? Are there other potential predictive biomarkers? |
| Social burden |
| What is the patients’ burden (financial, family planning, etc) of long-term treatment with IDH inhibitors? |
| What is the cost-effectiveness associated with vorasidenib? |
| How to improve access to treatment in developing countries? |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
